RC Dissociatives: 2F-DCK, DCK, O-PCE, FXE, DMXE and PCP/PCE Analogues
What the evidence actually shows
Evidence LowDirect answer
Evidence-based guide to research-chemical dissociatives including 2F-DCK, DCK, O-PCE, FXE, DMXE, MXiPr and PCP/PCE analogues, with poisoning patterns, forensic evidence, unconsciousness, seizures, hypertension, and product uncertainty. The modern RC dissociative market contains multiple ketamine- and PCP/PCE-like arylcyclohexylamines with very uneven human evidence. 2F-DCK has one of the stronger published human toxicology datasets, including a 20-case clinical series and later forensic deaths. Names frequently discussed online include DCK, O-PCE, 3-HO-PCP, 3-MeO-PCE, FXE, DMXE, MXiPr and MXPr.
Research brief
Questions this page answers
- What are RC dissociatives?
- What is 2F-DCK?
- What are FXE, DMXE and O-PCE?
- Can ketamine analogues cause seizures or loss of consciousness?
Signal
Scientific takeaways
- The modern RC dissociative market contains multiple ketamine- and PCP/PCE-like arylcyclohexylamines with very uneven human evidence.
- 2F-DCK has one of the stronger published human toxicology datasets, including a 20-case clinical series and later forensic deaths.
- Names frequently discussed online include DCK, O-PCE, 3-HO-PCP, 3-MeO-PCE, FXE, DMXE, MXiPr and MXPr.
- Severe presentations can include loss of consciousness, seizures, agitation, abnormal behavior, hypertension and injuries while dissociated.
RC Dissociatives: Ketamine and PCP/PCE Analogues
Quick answer
Research-chemical dissociatives are mostly arylcyclohexylamines related structurally or pharmacologically to ketamine, PCP, PCE, or methoxetamine.
Names repeatedly appearing in current RC discussions include:
- 2F-DCK;
- DCK;
- O-PCE;
- 3-HO-PCP;
- 3-MeO-PCE;
- FXE;
- DMXE;
- MXiPr;
- MXPr;
- newer FXE-like analogues.
The evidence is extremely uneven.
2F-DCK has clinical and forensic case series. Some newer compounds have almost no peer-reviewed human toxicology at all.
What makes this class risky?
Dissociation can impair:
- pain perception;
- balance;
- judgment;
- orientation;
- memory;
- awareness of danger.
A person can therefore be seriously impaired before recognizing that anything is wrong.
Published 2F-DCK cases show the range
A 2020 clinical series identified 20 analytically confirmed 2F-DCK exposures.
Reported problems were mainly neurological and cardiovascular, including:
- impaired consciousness;
- agitation;
- abnormal behavior;
- hypertension;
- tachycardia;
- loss of consciousness;
- convulsions.
Most cases also involved other ketamine-type drugs, which is a crucial limitation.
Later forensic literature documented deaths and severe behavioral events involving 2F-DCK.
Why “this one is basically ketamine” can be misleading
Minor structural changes can alter:
- metabolism;
- duration;
- potency;
- active metabolites;
- receptor selectivity;
- toxic concentrations.
A chemical can feel subjectively similar to ketamine while having a different time course or toxicology.
FXE and DMXE: popular, thin evidence
FXE and DMXE are frequently discussed online, especially as possible substitutes for MXE or ketamine.
The problem is that peer-reviewed human safety evidence is dramatically thinner than the discussion volume suggests.
That mismatch—high market visibility, low clinical evidence—is exactly why these compounds need dedicated pages that clearly label the data gaps.
Emergency warning signs
Urgent assessment is warranted for:
- inability to awaken;
- seizure;
- severe agitation or violent confusion;
- chest pain;
- major injury while intoxicated;
- abnormal breathing;
- very high blood pressure with neurologic symptoms;
- persistent psychosis-like symptoms.
High-priority profiles
DCK, FXE, DMXE, MXiPr and MXPr remain useful future targets where the human evidence can support more than an anecdote-driven profile.
Expanded individual profiles
Why dissociative analogues cannot be treated as interchangeable
A dissociative label describes a broad effect class, not a single predictable risk profile. Ketamine analogues, arylcyclohexylamines related to PCP, and newer compounds can differ in receptor activity, metabolism, duration, active metabolites, and the quality of human evidence. Structural similarity is useful for generating hypotheses, but it is not a validated conversion chart.
The evidence should be read in layers. Analytical studies can confirm identity in drug material or biological samples. Receptor studies can show NMDA-receptor activity and off-target effects. Case reports and poison-center data can document agitation, impaired consciousness, psychosis-like states, seizures, cardiovascular abnormalities, or injury. Controlled human pharmacokinetic data, however, remain absent for many RC dissociatives.
Acute safety and behavior
Dissociation itself can create risk even before a specific toxic mechanism is proven. Severe confusion, loss of coordination, reduced awareness of surroundings, panic, agitation, or unconsciousness can lead to falls, aspiration, exposure, traffic injury, or other trauma. Co-use with depressants can add sedation and airway risk; co-use with stimulants can complicate cardiovascular and behavioral toxicity.
Repeated exposure and recovery
Frequent use of dissociatives can be associated with tolerance, compulsive patterns, cognitive or mood effects, and—depending on the compound and exposure pattern—urinary-tract injury. The degree to which those risks transfer to each newer analogue is not always known. That uncertainty is a reason to avoid confident claims of “cleaner” or “safer” analogues based only on subjective reports.
Testing limitations
Routine toxicology screens may miss newer dissociatives. Definitive identification can require targeted or high-resolution mass spectrometry and an updated spectral library. A negative standard panel is therefore not proof that an NPS dissociative was absent.
This hub prioritizes compounds with published human toxicology or strong forensic evidence and keeps lower-signal names in discovery until the evidence can support a useful, source-grounded page.
Bottom line
The RC dissociative market contains compounds that may look like small variations on ketamine but have much thinner human safety data.
Online preference rankings cannot substitute for pharmacokinetic or toxicology evidence.
Source ledger
References
3 sources
- 01Emergence of new psychoactive substance 2-fluorodeschloroketamine Tang MHY, et al. · 2020PMID 32460225 PubMed →
- 02Ketamine analogues: Comparative toxicokinetic in vitro-in vivo extrapolation Forensic toxicokinetic study · 2020PMID 31881397 PubMed →
- 032-Fluorodeschloroketamine consumption: About two deaths and a case of self-mutilation Forensic case series · 2024PMID 38619360 PubMed →